For research use only. Not for therapeutic Use.
DG051 (Cat.No:I006472) is a novel compound with potential therapeutic applications. It acts as a selective antagonist of the chemokine receptor CXCR4, which plays a crucial role in cell migration and inflammation. DG051 shows promising anti-inflammatory and immunomodulatory effects and is being investigated for the treatment of autoimmune diseases and cancer.
| Catalog Number | I006472 |
| CAS Number | 929916-05-2 |
| Synonyms | DG-051; DG 051; DG051.;4-[(2S)-2-[4-(4-chlorophenoxy)phenoxymethyl]pyrrolidin-1-yl]butanoic acid |
| Molecular Formula | C21H24ClNO4 |
| Purity | ≥95% |
| Target | LTA4H Inhibitor |
| Solubility | Soluble in DMSO |
| Storage | 0 - 4°C for short term or -20 °C for long term |
| IUPAC Name | 4-[(2S)-2-[[4-(4-chlorophenoxy)phenoxy]methyl]pyrrolidin-1-yl]butanoic acid |
| InChI | InChI=1S/C21H24ClNO4/c22-16-5-7-19(8-6-16)27-20-11-9-18(10-12-20)26-15-17-3-1-13-23(17)14-2-4-21(24)25/h5-12,17H,1-4,13-15H2,(H,24,25)/t17-/m0/s1 |
| InChIKey | PVCTYSQBVIGZRU-KRWDZBQOSA-N |
| SMILES | C1CC(N(C1)CCCC(=O)O)COC2=CC=C(C=C2)OC3=CC=C(C=C3)Cl |
| Reference | </br>1:Discovery of 4-[(2S)-2-{[4-(4-chlorophenoxy)phenoxy]methyl}-1-pyrrolidinyl]butanoic acid (DG-051) as a novel leukotriene A4 hydrolase inhibitor of leukotriene B4 biosynthesis. Sandanayaka V, Mamat B, Mishra RK, Winger J, Krohn M, Zhou LM, Keyvan M, Enache L, Sullins D, Onua E, Zhang J, Halldorsdottir G, Sigthorsdottir H, Thorlaksdottir A, Sigthorsson G, Thorsteinnsdottir M, Davies DR, Stewart LJ, Zembower DE, Andresson T, Kiselyov AS, Singh J, Gurney ME.J Med Chem. 2010 Jan 28;53(2):573-85. doi: 10.1021/jm900838g. PMID: 19950900 </br>2:Synthesis and structural assignment of two major metabolites of the LTA4H inhibitor DG-051. Enache LA, Zhang J, Sullins DW, Kennedy I, Onua E, Zembower DE, Muellner FW, Singh J, Kiselyov AS.Bioorg Med Chem Lett. 2009 Nov 15;19(22):6275-9. doi: 10.1016/j.bmcl.2009.09.097. Epub 2009 Sep 29. PMID: 19819140 |
